Irritable Bowel Syndrome: Contemporary Management Approaches, Limitations, and Future Directions.

Authors

Imran Ahmed, Kunjan Chadha, Keshab R Paudel

Published in

Cureus. Volume 18. Issue 6. Pages e110741. Epub Jun 12, 2026.

Abstract

Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction characterized by recurrent abdominal pain associated with altered bowel habits in the absence of structural disease. Despite its high prevalence and substantial impact on quality of life, healthcare utilization, and long-term symptom burden, IBS management remains challenging because of its heterogeneous pathophysiology and variable treatment response. Current evidence supports a multifactorial model involving altered motility, visceral hypersensitivity, dysregulated brain-gut signaling, mucosal immune activation, microbiome changes, and intestinal barrier dysfunction, all of which contribute to the complexity of care. This narrative review summarizes contemporary management approaches for IBS, including dietary interventions, psychological therapies, pharmacologic treatments, biomarker-guided strategies, digital health technologies, and integrated care models. Particular attention is given to the low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) diet, soluble fiber, cognitive behavioral therapy (CBT), gut-directed hypnotherapy, subtype-specific pharmacologic agents, and emerging digital therapeutics that improve access to behavioral and self-management support. Although the literature demonstrates meaningful benefit across several treatment domains, important limitations remain, including short follow-up duration, lack of mechanistic stratification, inconsistent biomarker validation, and uncertainty regarding long-term treatment sequencing and personalization. Future progress in IBS care will likely depend on precision-oriented approaches that integrate clinical phenotyping, biologic markers, and multimodal treatment pathways tailored to individual patients. Continued emphasis on pragmatic trials, real-world implementation, and mechanism-based care models will be essential to improve outcomes and reduce the overall burden of IBS.

PMID:
42438663
Bibliographic data and abstract were imported from PubMed on 13 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.